Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Kondoh Y, Terasaka T, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Nakazawa T, Hirano M. Kuriwaki I, et al. Among authors: kondoh y. Bioorg Med Chem. 2021 Mar 1;33:116019. doi: 10.1016/j.bmc.2021.116019. Epub 2021 Jan 16. Bioorg Med Chem. 2021. PMID: 33486159
Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.
Iikubo K, Kurosawa K, Matsuya T, Kondoh Y, Kamikawa A, Moritomo A, Iwai Y, Tomiyama H, Shimada I. Iikubo K, et al. Among authors: kondoh y. Bioorg Med Chem. 2019 Apr 15;27(8):1683-1692. doi: 10.1016/j.bmc.2019.03.018. Epub 2019 Mar 7. Bioorg Med Chem. 2019. PMID: 30878193
Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M. Kuriwaki I, et al. Among authors: kondoh y. Bioorg Med Chem. 2020 May 15;28(10):115453. doi: 10.1016/j.bmc.2020.115453. Epub 2020 Mar 28. Bioorg Med Chem. 2020. PMID: 32278710
Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.
Iikubo K, Kondoh Y, Shimada I, Matsuya T, Mori K, Ueno Y, Okada M. Iikubo K, et al. Among authors: kondoh y. Chem Pharm Bull (Tokyo). 2018;66(3):251-262. doi: 10.1248/cpb.c17-00784. Chem Pharm Bull (Tokyo). 2018. PMID: 29491259 Free article.
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S. Mori M, et al. Among authors: kondoh y. Mol Cancer Ther. 2014 Feb;13(2):329-40. doi: 10.1158/1535-7163.MCT-13-0395. Epub 2014 Jan 13. Mol Cancer Ther. 2014. PMID: 24419060
521 results